ArticleSynthetic and systems biotechnology2026
A cell-free system for 1,6-hexanediamine synthesis using bulk chemical caprolactam as the feedstock.
Article in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomanufacturing, with its advantages of mildness, low carbon emissions, and renewability, drives the frontier of green chemistry and sustainable development. However, complex metabolic pathways and intracellular resource competition frequently limit the efficiency and yield of metabolic engineering approaches, particularly for non-natural compounds such as 1,6-hexanediamine (1,6-HMD), an important precursor for nylon 66. To address these challenges, we developed a cell-free biocatalytic system employing 6-aminocaproic acid (6-ACA), derived from low-cost caprolactam, together with optimized enzyme assembly and cofactor regeneration. As a result, the 1,6-hexanediamine titer was enhanced by 511-fold, reaching a record-high level of 10.35 g/L with a conversion rate of 97.4%. The system was further extended to the production of C7-C10 α,ω-diamines, achieving high-level titers. In addition, the cell-free biocatalytic system retained considerable activity after 7 days of storage at 4 °C, with a 25.9% reduction in titer. This cell-free biocatalysis overcame the inherent limitations of biological systems and preserved enzyme activity, demonstrating the substantial potential for efficient diamine synthesis and indicating broad applicability for future practical implementations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.